Valion Bio (VBIO) Change in Accured Expenses (2021 - 2025)
Valion Bio (VBIO) posted quarterly Change in Accured Expenses of $209000.0 for Q4 2025, up 361.25% year-over-year from $45311.7 in Q4 2024, and up 163.91% quarter-over-quarter from -$327000.0 in Q3 2025.
Valion Bio (VBIO) Change in Accured Expenses (2021 - 2025) Analysis & Trends
Valion Bio's Change in Accured Expenses history runs 5 years deep, the most recent figure standing at $209000.0 for Q4 2025.
- In Q4 2025, Change in Accured Expenses rose 361.25% year-over-year to $209000.0; the TTM figure through Dec 2025 stood at $235000.0 (up 167.53% YoY), while the FY2025 annual figure was $235000.0, up 167.53% from the prior year.
- Change in Accured Expenses for Q4 2025 stood at $209000.0, up from -$327000.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $287000.0 in Q4 2023, with the low at -$327000.0 in Q3 2025.
- The 5-year median for Change in Accured Expenses is -$1500.0 (2021), against an average of $11350.0.
- The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses jumped 394.87% in 2022, then plunged 1430.0% in 2023.
- Valion Bio's Change in Accured Expenses stood at -$39000.0 in 2021, then surged by 394.87% to $115000.0 in 2022, then surged by 149.57% to $287000.0 in 2023, then slumped by 127.87% to -$80000.0 in 2024, then jumped by 361.25% to $209000.0 in 2025.
- Business Quant data shows VBIO's Change in Accured Expenses at $209000.0 in Q4 2025, -$327000.0 in Q3 2025, and $197000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Valion Bio | 405,599.63 | -1.79 Mn | -45,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 209,000.00 |
| Dec 31, 2025 | 209,000.00 |
| Sep 30, 2025 | -327,000.00 |
| Sep 30, 2025 | -327,000.00 |
| Jun 30, 2025 | 197,000.00 |
| Jun 30, 2025 | 197,000.00 |
| Mar 31, 2025 | 156,000.00 |
| Mar 31, 2025 | 156,000.00 |
| Dec 31, 2024 | -80,000.00 |
| Dec 31, 2024 | -80,000.00 |
| Sep 30, 2024 | 82,000.00 |
| Sep 30, 2024 | 82,000.00 |
| Jun 30, 2024 | -120,000.00 |
| Jun 30, 2024 | -120,000.00 |
| Mar 31, 2024 | -230,000.00 |
| Mar 31, 2024 | -230,000.00 |
| Dec 31, 2023 | 287,000.00 |
| Dec 31, 2023 | 287,000.00 |
| Sep 30, 2023 | 45,000.00 |
| Sep 30, 2023 | 45,000.00 |